Schwab Charles Investment Management Inc. Purchases 31,857 Shares of Akebia Therapeutics Inc (AKBA)

Schwab Charles Investment Management Inc. boosted its position in Akebia Therapeutics Inc (NASDAQ:AKBA) by 15.4% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 238,333 shares of the biopharmaceutical company’s stock after purchasing an additional 31,857 shares during the quarter. Schwab Charles Investment Management Inc.’s holdings in Akebia Therapeutics were worth $4,689,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Akebia Therapeutics by 10.3% in the 2nd quarter. Vanguard Group Inc. now owns 1,436,163 shares of the biopharmaceutical company’s stock valued at $20,638,000 after acquiring an additional 134,283 shares in the last quarter. FMR LLC raised its holdings in Akebia Therapeutics by 11.3% in the 2nd quarter. FMR LLC now owns 1,036,955 shares of the biopharmaceutical company’s stock valued at $14,901,000 after acquiring an additional 105,100 shares in the last quarter. Renaissance Technologies LLC raised its holdings in Akebia Therapeutics by 165.4% in the 2nd quarter. Renaissance Technologies LLC now owns 1,025,300 shares of the biopharmaceutical company’s stock valued at $14,734,000 after acquiring an additional 639,033 shares in the last quarter. State Street Corp raised its holdings in Akebia Therapeutics by 72.9% in the 2nd quarter. State Street Corp now owns 946,888 shares of the biopharmaceutical company’s stock valued at $13,604,000 after acquiring an additional 399,160 shares in the last quarter. Finally, RA Capital Management LLC acquired a new position in Akebia Therapeutics in the 2nd quarter valued at $12,018,000. Institutional investors and hedge funds own 62.73% of the company’s stock.

Akebia Therapeutics Inc (NASDAQ AKBA) opened at $15.25 on Thursday. Akebia Therapeutics Inc has a fifty-two week low of $8.58 and a fifty-two week high of $20.25. The company has a market capitalization of $720.85, a price-to-earnings ratio of -4.83 and a beta of 0.87.

Akebia Therapeutics (NASDAQ:AKBA) last posted its quarterly earnings results on Wednesday, November 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.56) by $0.07. Akebia Therapeutics had a negative return on equity of 198.85% and a negative net margin of 137.80%. The company had revenue of $41.28 million during the quarter, compared to analysts’ expectations of $34.00 million. equities research analysts anticipate that Akebia Therapeutics Inc will post -2.25 earnings per share for the current year.

Several brokerages have weighed in on AKBA. Mizuho began coverage on Akebia Therapeutics in a report on Wednesday, October 4th. They issued a “buy” rating and a $24.00 price objective for the company. Zacks Investment Research cut Akebia Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Royal Bank of Canada reissued a “hold” rating and set a $17.00 price target on shares of Akebia Therapeutics in a report on Thursday, November 2nd. ValuEngine cut Akebia Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, December 1st. Finally, BTIG Research began coverage on Akebia Therapeutics in a report on Thursday, December 7th. They set a “buy” rating and a $30.00 price target for the company. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and eight have issued a buy rating to the stock. Akebia Therapeutics currently has an average rating of “Buy” and a consensus target price of $22.20.

WARNING: This piece was originally reported by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.themarketsdaily.com/2018/01/11/schwab-charles-investment-management-inc-purchases-31857-shares-of-akebia-therapeutics-inc-akba.html.

Akebia Therapeutics Company Profile

Akebia Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company’s lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD).

Want to see what other hedge funds are holding AKBA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Akebia Therapeutics Inc (NASDAQ:AKBA).

Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)

Receive News & Ratings for Akebia Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akebia Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply